Obinutuzumab (anti-CD20)

Catalog No.A2023 Synonyms: Gazyva, GA101, Gazyvaro, Afutuzumab

For research use only.
Not for use in humans.

Obinutuzumab (anti-CD20) (Gazyva, GA101, Gazyvaro, Afutuzumab) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed for lymphocytic leukemia and lymphoma of B-cell origin. MW : 146.1 kD.

Quality Control

Choose Selective CD markers Inhibitors

Biological Activity

Description Obinutuzumab (anti-CD20) (Gazyva, GA101, Gazyvaro, Afutuzumab) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed for lymphocytic leukemia and lymphoma of B-cell origin. MW : 146.1 kD.
In vitro

GA101 is the first Fc-engineered, type II humanized IgG1 antibody against CD20. Relative to rituximab, GA101 has increased direct and immune effector cell-mediated cytotoxicity and exhibits superior activity in cellular assays and whole blood B-cell depletion assays.[3]

In vivo

In human lymphoma xenograft models, GA101 exhibits superior antitumor activity, resulting in the induction of complete tumor remission and increased overall survival. In nonhuman primates, GA101 demonstrates superior B cell–depleting activity in lymphoid tissue, including in lymph nodes and spleen.[3]

Protocol

Cell Research:
- Collapse
  • Objective: Annexin V/PI FACS assay
    Cells: NHL cell lines
    Concentrations: 10 μg/mL
    Incubation Time: 36 hr
    Method: For CD40 stimulation of hCD20 cells from transgenic mice, red blood cells (RBCs) are removed by hypotonic ammonium-chloride-potassium (ACK) lysis, and untouched splenic B cells are purified by anti-CD43–mediated depletion of non-B cells (MACS). B cells are incubated in conditioned complete RPMI 1640 medium containing 10% fetal bovine serum for 2 hours (with or without 10 μg/mL mitogenic stimulation) and either anti-CD40 or anti-IgM Fab2 antibodies. This is followed by 36 hours of anti-CD20 stimulation (GA101 or rituximab 10 μg/mL). As positive controls for the induction of cell death, the following agents are used: 100nM staurosporine for mitochondrial-mediated apoptosis, or 1 μg/mL anti-CD95 Fas for the extrinsic induction of apoptosis.
    Reference: https://pubmed.ncbi.nlm.nih.gov/20194898/

    Obinutuzumab can apply to humanized mice (eg:SCID beige mice), peripheral blood and other related assays (Only for Reference)

Animal Research:
- Collapse
  • Objective: Tumor control ratio (TCR) and tumor growth inhibition (TGI)
    Animal Models: 4- to 8-week-old female SCID beige mice
    Formulation: --
    Dosages: 30 mg/kg
    Administration: i.p.
    Reference: https://pubmed.ncbi.nlm.nih.gov/24304419/

    Objective: NHL xenograft studies in SCID beige mice
    Animal Models: 4 to 5-week-old female SCID beige mice
    Formulation: --
    Dosages: 10 mg/kg, 30 mg/kg
    Administration: i.p.
    Reference: https://pubmed.ncbi.nlm.nih.gov/20194898/

    Obinutuzumab can apply to humanized mice (eg:SCID beige mice), peripheral blood and other related assays (Only for Reference)

Product Details

CAS No. 949142-50-1
Formulation PBS buffer, pH 7.2
Isotype Humanized IgG1
Source Humanized (from mouse)
Storage Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy Obinutuzumab (anti-CD20) | Obinutuzumab (anti-CD20) supplier | purchase Obinutuzumab (anti-CD20) | Obinutuzumab (anti-CD20) cost | Obinutuzumab (anti-CD20) manufacturer | order Obinutuzumab (anti-CD20) | Obinutuzumab (anti-CD20) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID